Thrivent Financial for Lutherans Purchases 11,904 Shares of Bristol Myers Squibb Company $BMY

Thrivent Financial for Lutherans lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 163,460 shares of the biopharmaceutical company’s stock after purchasing an additional 11,904 shares during the period. Thrivent Financial for Lutherans’ holdings in Bristol Myers Squibb were worth $7,372,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BMY. Trifecta Capital Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Harbor Capital Advisors Inc. boosted its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the last quarter. REAP Financial Group LLC grew its position in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares during the period. Finally, Total Investment Management Inc. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $38,000. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BMY shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Piper Sandler reaffirmed an “overweight” rating and set a $66.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Finally, Leerink Partners increased their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $57.43.

Bristol Myers Squibb Trading Up 3.1%

Shares of Bristol Myers Squibb stock opened at $59.43 on Friday. The company’s 50-day moving average price is $54.08 and its 200-day moving average price is $48.92. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a market cap of $120.99 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 0.18 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue and underlying growth beat consensus and management highlighted a 16% jump in the growth portfolio, helping offset declines in older drugs; quarterly revenue was $12.5B. BMY beats Q4 estimates
• Positive Sentiment: Management set FY‑2026 guidance above consensus (EPS 6.05–6.35 and revenue $46.0–$47.5B), which the market interpreted as an especially upbeat outlook for next year. Reuters: forecasts upbeat 2026
• Positive Sentiment: CEO and management commentary stressed a deeper late‑stage pipeline and multiple upcoming catalysts — messaging that reassured investors about medium‑term growth potential. CNBC interview with CEO
• Positive Sentiment: Company is investing in new manufacturing and growth engines (expanded Opti manufacturing arrangements and other business development moves) intended to support launches and supply for growth products. TipRanks: bets on new growth engines
• Neutral Sentiment: The company published the full earnings presentation and call transcript — useful for digging into product‑level trends and assumptions behind guidance. Earnings presentation
• Negative Sentiment: Management expects overall sales to decline this year versus 2025 (guidance is below 2025 revenue), largely reflecting continued headwinds from legacy products and planned Eliquis pricing moves — a near‑term revenue headwind even if management says the pricing strategy will pay off longer term. MSN: sales to decline this year
• Negative Sentiment: Reported EPS dynamics are mixed: non‑GAAP EPS and some vendor estimates were beat, but year‑over‑year EPS declined and some consensus measures showed a miss — contributing to investor debate over near‑term profitability vs longer‑term growth. Business Wire: official results

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.